The EU-funded research project BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis) kicks off its activities with the aim of improving the lives of patients affected by the two most common inflammatory skin conditions. Addressing key unmet needs in treating atopic dermatitis and psoriasis by analysing data from more than 50 000 patients, the five-year project will have a broad impact on disease understanding, patient care and future therapies.The team comprises 26 academic and five industry partners as well as five patient organisations. By analysing the largest collection of patient data ever and performing advanced molecular investigations at the single cell level and in the tissue context, they aim at identifying biomarkers for variations in disease outcome.
The European Innovative Medicines Initiative (IMI) and the participating pharma companies provide EUR 20.8 million funding for the first IMI project in the field of dermatology. The Laboratory for Experimental Dermatology, dept. Of Dermatology headed by Ellen van den Bogaard, theme Inflammatory diseases, leads the research on the experimental validation and functional analysis of identified biomarkers by using advanced organotypic skin models and receives a grant of €258,000.
Related news items
A personal touch of Laura Diepeveen12 September 2019
In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Laura Diepeveen.read more
Yvonne Engels appointed Professor of Spiritual Healthcare10 September 2019
Engels is an expert in the field of palliative care: optimising patients’ quality of life when healing is no longer possible.read more